...
首页> 外文期刊>Bioorganic and medicinal chemistry >Design, synthesis, and biological evaluation of some novel indolizine derivatives as dual cyclooxygenase and lipoxygenase inhibitor for anti-inflammatory activity
【24h】

Design, synthesis, and biological evaluation of some novel indolizine derivatives as dual cyclooxygenase and lipoxygenase inhibitor for anti-inflammatory activity

机译:一些新型吲哚嗪衍生物的设计,合成和生物学评价为双环氧基酶和脂氧合酶抑制剂的抗炎活性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Graphical abstract Display Omitted Abstract Some novel indolizine derivatives were synthesized by bioisosteric modification of imidazo[1,2- a ]pyridine for anti-inflammatory activity. The physicochemical characterization and structure of compounds were elucidated by state of the art spectroscopic technique. Induced fit docking was performed for initial screening to elucidate the interactions with corresponding amino acids of cyclooxygenase (COX-1, COX-2) and lipoxygenase (LOX) enzymes. The target compounds 53 – 60 were then evaluated against in vivo carrageenan and arachidonic acid induced rat paw edema models for anti-inflammatory activity. Amongst all the synthesized derivatives, compound 56 showed the significant anti-inflammatory activity in both rat paw edema models with very less ulcerogenic liability in comparison to standard diclofenac, celecoxib, and zileuton. The compounds 56 was further assessed to observe in vitro enzyme inhibition assay on both cyclooxygenase and lipoxygenase enzyme where it showed a preferential and selective non-competitive enzyme inhibition towards the COX-2 (IC 50 = 14.91 μM, Ki = 0.72 μM) over COX-1 (IC 50 50 μM) and a significant non-competitive inhibition of soybean lipoxygenase enzyme (IC 50 = 13.09 μM, Ki = 0.92 μM). Thus, in silico, in vivo , and in vitro findings suggested that the synthesized indolizine compound 56 has a dual COX-2 and LOX inhibition characteristic and parallel in vivo anti-inflammatory activity in comparison to the standard drugs. ]]>
机译:图形摘要显示显示摘要摘要一些新的吲哚嗪衍生物被咪唑酯改性合成了咪唑[1,2- a]吡啶用于抗炎活性。通过现实的光谱技术阐明了化合物的物理化学表征和结构。对初始筛选进行诱导的配合对接,以阐明与环氧化酶(COX-1,COX-2)和脂氧合酶(LOX)酶的相应氨基酸的相互作用。然后在体内角叉菜胶和花生酸诱导的大鼠爪子水肿模型中评估靶化合物53-60,用于抗炎活性。在所有合成的衍生物中,化合物56在与标准的双氯芬酸,Celecoxib和Zileuton相比,大鼠爪子水肿模型中的大鼠爪子水肿模型具有非常较小的溃疡性抗炎症。进一步评估化合物56以观察在环氧氧酶和脂氧合酶的体外酶抑制测定中,在那里它在COX上显示了朝向COX-2(IC 50 =14.91μm,ki =0.72μm)的优先和选择性的非竞争性酶抑制-1(IC 50&50μm)和大豆脂氧合酶的显着不竞争抑制(IC 50 =13.09μm,ki =0.92μm)。因此,在硅中,体内和体外发现表明,合成的吲哚嗪化合物56具有与标准药物相比的体内抗炎活性的双COX-2和LOX抑制特性和平行。 ]]>

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号